455 related articles for article (PubMed ID: 30919786)
1. Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats.
Rahman MA; Harwansh RK; Iqbal Z
Pharm Nanotechnol; 2019; 7(2):162-176. PubMed ID: 30919786
[TBL] [Abstract][Full Text] [Related]
2. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
[TBL] [Abstract][Full Text] [Related]
3. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery.
Dong Z; Xie S; Zhu L; Wang Y; Wang X; Zhou W
Drug Deliv; 2011 Aug; 18(6):441-50. PubMed ID: 21554156
[TBL] [Abstract][Full Text] [Related]
4. Sustained release of piroxicam from solid lipid nanoparticle as an effective anti-inflammatory therapeutics in vivo.
Peng LH; Wei W; Shan YH; Chong YS; Yu L; Gao JQ
Drug Dev Ind Pharm; 2017 Jan; 43(1):55-66. PubMed ID: 27498809
[TBL] [Abstract][Full Text] [Related]
5. Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability.
Ibrahim WM; AlOmrani AH; Yassin AE
Int J Nanomedicine; 2014; 9():129-44. PubMed ID: 24379671
[TBL] [Abstract][Full Text] [Related]
6. Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics.
Cirri M; Mennini N; Maestrelli F; Mura P; Ghelardini C; Di Cesare Mannelli L
Int J Pharm; 2017 Apr; 521(1-2):73-83. PubMed ID: 28229944
[TBL] [Abstract][Full Text] [Related]
7. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability.
Tran TH; Ramasamy T; Cho HJ; Kim YI; Poudel BK; Choi HG; Yong CS; Kim JO
J Nanosci Nanotechnol; 2014 Jul; 14(7):4820-31. PubMed ID: 24757949
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
9. Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Gambhire VM; Gambhire MS; Ranpise NS
Pharm Nanotechnol; 2019; 7(5):375-388. PubMed ID: 31376827
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability.
Kushwaha AK; Vuddanda PR; Karunanidhi P; Singh SK; Singh S
Biomed Res Int; 2013; 2013():584549. PubMed ID: 24228255
[TBL] [Abstract][Full Text] [Related]
11. Lyophilized SLN of Cinnacalcet HCl: BBD enabled optimization, characterization and pharmacokinetic study.
Routray SB; Patra CN; Raju R; Panigrahi KC; Jena GK
Drug Dev Ind Pharm; 2020 Jul; 46(7):1080-1091. PubMed ID: 32486863
[No Abstract] [Full Text] [Related]
12. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach.
Makwana V; Jain R; Patel K; Nivsarkar M; Joshi A
Int J Pharm; 2015 Nov; 495(1):439-446. PubMed ID: 26367780
[TBL] [Abstract][Full Text] [Related]
13. Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles.
Lingling G; Yuan Z; Weigen L
Drug Dev Ind Pharm; 2016 Aug; 42(8):1325-33. PubMed ID: 26821124
[TBL] [Abstract][Full Text] [Related]
14. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
16. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
Das S; Ng WK; Kanaujia P; Kim S; Tan RB
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):483-9. PubMed ID: 21831615
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of solid lipid nanoparticles containing peptide.
Hu FQ; Hong Y; Yuan H
Int J Pharm; 2004 Apr; 273(1-2):29-35. PubMed ID: 15010127
[TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
19. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters.
Shah B; Khunt D; Bhatt H; Misra M; Padh H
Eur J Pharm Sci; 2015 Oct; 78():54-66. PubMed ID: 26143262
[TBL] [Abstract][Full Text] [Related]
20. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers.
Thatipamula R; Palem C; Gannu R; Mudragada S; Yamsani M
Daru; 2011; 19(1):23-32. PubMed ID: 22615636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
